¼¼°èÀÇ À§¾Ï Ä¡·áÁ¦ ½ÃÀå(2025-2029³â)
Global Gastric Cancer Drugs Market 2025-2029
»óǰÄÚµå : 1727157
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 05¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 217 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,443,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,508,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

À§¾Ï Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â¿¡ 260¾ï 3,500¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø±â°£ Áß CAGRÀº 20.6%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

À§¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¡¤¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´Ù·é º¥´õ ºÐ¼® µîÀ» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.

ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. À§¾Ï¿¡ ´ëÇÑ ÀǽÄÀÇ Çâ»ó Ä·ÆäÀÎ Áõ°¡, Àü ¼¼°è ³ëÀÎ Àα¸ Áõ°¡, À§¾Ï À¯º´·ü Áõ°¡¿¡ ÀÇÇØ ½ÃÀåÀÌ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ¿¬µµ 2025
Á¾·á¿¬µµ 2029
¿¹Ãø ±â°£ 2025-2029
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â´ëºñ 16.6%
CAGR 20.6%
Áõ°¡¾× 260¾ï 3,500¸¸ ´Þ·¯

º» Á¶»ç´Â ¾÷°èÀÇ ÁÖ¿ä Âü°¡ÀڷκÎÅÍÀÇ ÀÎDzÀ» Æ÷ÇÔÇÑ 1Â÷ Á¤º¸¿Í 2Â÷ Á¤º¸ÀÇ °´°üÀûÀÎ Á¶ÇÕÀ» »ç¿ëÇÏ¿© ½ÃÇàÇß½À´Ï´Ù. ¸®Æ÷Æ®¿¡´Â ÁÖ¿ä ±â¾÷ÀÇ ºÐ¼®°ú ÇÔ²² Á¾ÇÕÀû ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ª ºÐ¼®¿¡ ÀÇÇÑ ºÎ¹®, º¥´õ ±¸µµ°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¸®Æ÷Æ®¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÇâÈÄ ¼ö³â°£ À§¾Ï Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î ÀǾàǰÀÇ ½ÂÀÎ ¹× Ãâ½Ã Áõ°¡¸¦ ²Å¾Ò½À´Ï´Ù. ¶ÇÇÑ À§¾Ï Ä¡·áÁ¦ÀÇ °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀΰú ±â¾÷ÀÇ ¿¬±¸°³¹ß Áõ°¡´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå ±¸µµ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦6Àå Á¤¼º ºÐ¼®

Á¦7Àå Five Forces ºÐ¼®

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : Åõ¿© °æ·Îº°

Á¦9Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦10Àå ½ÃÀå ¼¼ºÐÈ­ : ¾àÁ¦ Ŭ·¡½ºº°

Á¦11Àå °í°´ »óȲ

Á¦12Àå Áö¿ªº° »óȲ

Á¦13Àå ÃËÁø¿äÀΡ¤°úÁ¦¡¤±âȸ¡¤¾ïÁ¦¿äÀÎ

Á¦14Àå °æÀï ±¸µµ

Á¦15Àå °æÀï ºÐ¼®

Á¦16Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The gastric cancer drugs market is forecasted to grow by USD 26,035 mn during 2024-2029, accelerating at a CAGR of 20.6% during the forecast period. The report on the gastric cancer drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing awareness campaigns for gastric cancer, growing geriatric population globally, and increasing prevalence of gastric cancer.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 202516.6%
CAGR20.6%
Incremental Value$26,035 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's gastric cancer drugs market is segmented as below:

By Route Of Administration

By Distribution Channel

By Drug Class

By Geographical Landscape

This study identifies the increase in number of drug approvals and drug launches as one of the prime reasons driving the gastric cancer drugs market growth during the next few years. Also, strong pipeline of gastric cancer drugs and increasing research and development by companies will lead to sizable demand in the market.

The report on the gastric cancer drugs market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading gastric cancer drugs market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Biocon Ltd., Blueprint Medicines Corp., Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Celltrion Co. Ltd., Dr Reddys Laboratories Ltd., Eisai Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi SA, and Zydus Lifesciences Ltd.. Also, the gastric cancer drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Historic Market Size

6 Qualitative Analysis

7 Five Forces Analysis

8 Market Segmentation by Route of Administration

9 Market Segmentation by Distribution Channel

10 Market Segmentation by Drug Class

11 Customer Landscape

12 Geographic Landscape

13 Drivers, Challenges, and Opportunity/Restraints

14 Competitive Landscape

15 Competitive Analysis

16 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â